Analysts Set Altimmune, Inc. (NASDAQ:ALT) PT at $20.00

Altimmune, Inc. (NASDAQ:ALT) has received an average recommendation of “Moderate Buy” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.00.

Several brokerages have recently weighed in on ALT. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th. B. Riley reissued a “buy” rating and set a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. Finally, UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target on the stock.

Institutional Trading of Altimmune

A number of hedge funds have recently bought and sold shares of ALT. Larson Financial Group LLC bought a new stake in Altimmune during the third quarter valued at about $31,000. CANADA LIFE ASSURANCE Co purchased a new position in shares of Altimmune in the 1st quarter worth approximately $44,000. TFO Wealth Partners LLC purchased a new position in shares of Altimmune in the 1st quarter worth approximately $51,000. Horizon Wealth Management LLC bought a new position in shares of Altimmune during the 2nd quarter worth approximately $66,000. Finally, PFG Investments LLC purchased a new stake in Altimmune during the second quarter valued at approximately $67,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Stock Up 3.3 %

ALT stock opened at $8.68 on Monday. The firm’s fifty day simple moving average is $7.11 and its two-hundred day simple moving average is $6.94. The stock has a market capitalization of $617.37 million, a price-to-earnings ratio of -5.60 and a beta of 0.09. Altimmune has a twelve month low of $2.50 and a twelve month high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the company posted ($0.39) earnings per share. As a group, equities research analysts expect that Altimmune will post -1.36 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.